Stonegate Capital Partners Updates Coverage on NeOnc Technologies' CNS Oncology Pipeline

Stonegate Capital Partners has updated its coverage of NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage CNS oncology company developing therapies designed to overcome the blood-brain barrier and improve drug delivery to the brain. The company's lead program, NEO212, represents a next-generation version of temozolomide, the standard-of-care chemotherapy used in most brain cancer patients. This therapy is specifically engineered to address key limitations of current treatment, including blood-brain barrier penetration and MGMT-driven resistance, targeting a large population where standard temozolomide therapy frequently fails.

Clinical momentum for NEO212 continues to build, with Phase 1 dose escalation in recurrent glioblastoma completed and a Recommended Phase 2 Dose of 610 mg established. Early signs of disease control have been observed, positioning the program to advance into Phase 2 efficacy evaluation. Beyond this lead program, NeOnc's platform approach combines intranasal and oral drug delivery technologies designed to improve CNS drug penetration, supporting additional opportunities across multiple brain tumor indications. The company's other key program, NEO100, utilizes a non-invasive intranasal delivery approach targeting recurrent glioblastoma, with Phase 2 data showing radiographic responses and improved progression-free survival versus historical salvage benchmarks.

NeOnc Technologies recently strengthened its financial position through a successful PIPE offering, adding a gross $16.0 million to the company's balance sheet. This capital infusion provides additional resources to advance the company's pipeline programs through clinical development. The company's therapeutic approach addresses significant unmet needs in neuro-oncology, where effective treatment options remain limited due to the protective nature of the blood-brain barrier. By developing technologies that enhance drug delivery to the brain, NeOnc aims to improve outcomes for patients with various brain tumor types.

Stonegate Capital Partners, a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies, has maintained coverage of NeOnc Technologies as the company progresses its clinical programs. The full announcement, including downloadable images and additional details, is available through Stonegate's reporting platform. The updated coverage reflects ongoing developments in NeOnc's pipeline and the company's strategic positioning within the CNS oncology therapeutic landscape.